Related Experiment Video

Updated: Jun 22, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.5K

The therapeutic role of γδT cells in TNBC

Wenjing Li1, Xian Zhao1, Chuanxin Ren2

  • 1Department of Breast Center, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China.

Frontiers in Immunology
|June 27, 2024
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks effective treatments. Gamma delta T (γδT) cells show promise for TNBC immunotherapy due to their potent anti-tumor activity and ability to target cancer cells directly.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Triple-negative breast cancer (TNBC) presents therapeutic challenges due to its unique molecular profile (ER-, PR-, HER2-).
  • Current treatments for TNBC are limited, necessitating the exploration of novel therapeutic strategies.
  • Gamma delta T (γδT) cells possess inherent anti-tumor capabilities and can target cancer cells irrespective of MHC presentation.

Purpose of the Study:

  • To review the potential of γδT cells as a therapeutic strategy for TNBC.
  • To discuss the mechanisms by which γδT cells exert anti-tumor effects in the context of TNBC.
  • To explore future directions for γδT cell-based immunotherapies for TNBC.

Main Methods:

  • Literature review of preclinical and clinical studies on γδT cells and TNBC.
  • Analysis of γδT cell subtypes (Vδ2 and Vδ1) and their roles in anti-tumor immunity.
  • Discussion of adoptive transfer and expansion strategies for γδT cell therapy.

Main Results:

  • γδT cells exhibit potent cytotoxic effects against TNBC cells.
  • γδT cells can modulate the tumor microenvironment and enhance anti-tumor immune responses.
  • Preclinical models show promise for Vδ2 and Vδ1 γδT cell-based therapies in TNBC.

Conclusions:

  • γδT cells represent a promising cellular immunotherapy for TNBC.
  • Further research into γδT cell expansion and adoptive transfer strategies is warranted.
  • Targeting γδT cell subsets could lead to effective novel treatments for TNBC.
Keywords:
TNBCbreast cancergamma delta T cellimmunotherapyγδT cell

More Related Videos

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product11:51

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

9.0K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
888
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K